| SKŘIČKOVÁ, Jana, M PESEK, P OPALKA, L KOUBKOVA, M ZEMANOVA, M HRNCIARIK, J BLAZEK, M SVATON, J KREJCI, H COUPKOVA, D DOLEZAL, T TUZOVA, L HOLUBEC, P MAHADEVIA, K SANDSTROM, P KUNOVSZKI, M BARINOVA, K HURDALKOVA, O FISCHER, M CERNOVSKA a M BRATOVA. Prognostic Value of EGFR Exon-20 Insertions in Czech Patients With Advanced Non-small Cell Lung Cancer. Anticancer Research. Athens: International Institute of Anticancer Research, 2021, roč. 41, č. 11, s. 5625-5634. ISSN 0250-7005. Dostupné z: https://dx.doi.org/10.21873/anticanres.15378. |
Další formáty:
BibTeX
LaTeX
RIS
@article{1807829,
author = {Skřičková, Jana and Pesek, M and Opalka, P and Koubkova, L and Zemanova, M and Hrnciarik, M and Blazek, J and Svaton, M and Krejci, J and Coupkova, H and Dolezal, D and Tuzova, T and Holubec, L and Mahadevia, P and Sandstrom, K and Kunovszki, P and Barinova, M and Hurdalkova, K and Fischer, O and Cernovska, M and Bratova, M},
article_location = {Athens},
article_number = {11},
doi = {http://dx.doi.org/10.21873/anticanres.15378},
keywords = {EGFR exon-20 insertions; NSCLC; prognostic values; RWE},
language = {eng},
issn = {0250-7005},
journal = {Anticancer Research},
note = {Bez afiliace k MU.},
title = {Prognostic Value of EGFR Exon-20 Insertions in Czech Patients With Advanced Non-small Cell Lung Cancer},
volume = {41},
year = {2021}
}
TY - JOUR
ID - 1807829
AU - Skřičková, Jana - Pesek, M - Opalka, P - Koubkova, L - Zemanova, M - Hrnciarik, M - Blazek, J - Svaton, M - Krejci, J - Coupkova, H - Dolezal, D - Tuzova, T - Holubec, L - Mahadevia, P - Sandstrom, K - Kunovszki, P - Barinova, M - Hurdalkova, K - Fischer, O - Cernovska, M - Bratova, M
PY - 2021
TI - Prognostic Value of EGFR Exon-20 Insertions in Czech Patients With Advanced Non-small Cell Lung Cancer
JF - Anticancer Research
VL - 41
IS - 11
SP - 5625-5634
EP - 5625-5634
PB - International Institute of Anticancer Research
SN - 02507005
N1 - Bez afiliace k MU.
KW - EGFR exon-20 insertions
KW - NSCLC
KW - prognostic values
KW - RWE
N2 - Background/Aim: Per literature, patients with epidermal growth factor receptor (EGFR) exon-20 insertions respond poorly to tyrosine kinase inhibitors (TKIs). This study analyzed real-world data to examine the prognostic and predictive value of these mutations. Patients and Methods: We conducted a retrospective cohort study using Czech TULUNG Registry data, with data on multiple mutation types, collected in 2011-2020. Results: We analyzed 554 (95.85%) patients with EGFR exon-19 deletions or exon-21 L858R substitutions and 24 (4.15%) patients with exon-20 insertions who received first-line high-value therapies. We summarized clinical characteristics and outcomes in all patients and by cohort. The risk of progression was statistically significantly higher (86%) in the exon-20 insertion cohort compared to the cohort with other mutations. Although not statistically significant, the risk of death was 44% higher in patients with exon-20 insertions. Conclusion: Advanced NSCLC patients with rare EGFR exon-20 insertions have a high risk of progression.
ER -
SKŘIČKOVÁ, Jana, M PESEK, P OPALKA, L KOUBKOVA, M ZEMANOVA, M HRNCIARIK, J BLAZEK, M SVATON, J KREJCI, H COUPKOVA, D DOLEZAL, T TUZOVA, L HOLUBEC, P MAHADEVIA, K SANDSTROM, P KUNOVSZKI, M BARINOVA, K HURDALKOVA, O FISCHER, M CERNOVSKA a M BRATOVA. Prognostic Value of EGFR Exon-20 Insertions in Czech Patients With Advanced Non-small Cell Lung Cancer. \textit{Anticancer Research}. Athens: International Institute of Anticancer Research, 2021, roč.~41, č.~11, s.~5625-5634. ISSN~0250-7005. Dostupné z: https://dx.doi.org/10.21873/anticanres.15378.
|
